Latest Trastuzumab Stories
Patients with HER2-positive breast cancer may have an alternative therapy when they develop resistance to trastuzumab, also known as Herceptin.
Better Targeting of Pharmaceuticals to Patient's Genetic Profile Could Save $30B - $110B Annually WASHINGTON, July 25, 2011 /PRNewswire-USNewswire/ -- Genetic testing made possible by the mapping of the human genome can help the US cut costs and create jobs while at the same time improving survival rates for such diseases as cancer, HIV, and heart disease. This according to Alan Mertz, president of the American Clinical Laboratory Association (ACLA): "Genetic testing is going to be a powerful...
Some of the most aggressive forms of breast cancer are more vulnerable to chemotherapy when it is combined with a new class of anti-cancer agent, researchers from the Walter and Eliza Hall Institute have shown.
The use of trastuzumab, chemotherapy and surgery among women with HER2-positive metastatic breast cancer significantly improved survival from the time central nervous system metastases were diagnosed.
There may be new hope for patients with advanced breast cancer.
SAN DIEGO, July 15, 2011 /PRNewswire/ -- Biocept, Inc. announced today that it has appointed William G. Kachioff as Senior Vice President, Finance and Chief Financial Officer. As CFO, Mr.
Part of agency's efforts to promote development of personalized medicines and diagnostics SILVER SPRING, Md., July 12, 2011 /PRNewswire-USNewswire/ --The U.S.
Adding AfinitorÂ® to HerceptinÂ®, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies.
Vanderbilt-Ingram Cancer Center researchers have identified six subtypes of an aggressive and difficult-to-treat form of breast cancer, called "triple-negative breast cancer (TNBC)."
TUCSON, Ariz., June 14, 2011 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced today that the FDA approved the INFORM HER2 Dual ISH DNA Probe cocktail assay (HER2 Dual ISH) for commercialization in the United States.